Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Evaluation of KRAS mutations, angiogenic biomarkers, and DCE-MRI in patients with advanced non-small-cell lung cancer receiving sorafenib.

Clinical cancer research : an official journal of the American Association for Cancer Research - 1 Mar 2011

Kelly Ronan J, Rajan Arun, Force Jeremy, Lopez-Chavez Ariel, Keen Corrine, Cao Liang, Yu Yunkai, Choyke Peter, Turkbey Baris, Raffeld Mark, Xi Liqiang, Steinberg Seth M, Wright John J, Kummar Shivaani, Gutierrez Martin, Giaccone Giuseppe

Abstract excerpt

PURPOSE: Sorafenib, a multikinase inhibitor targeting Raf and VEGFR, has shown activity in unselected patients with non-small-cell lung cancer (NSCLC). At present there are no validated biomarkers indicative of sorafenib activity. EXPERIMENTAL DESIGN: Patients received sorafenib 400 mg BID daily to determine activity and tolerability and to measure its biological effects. KRAS mutation status (N = 34),...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Angiogenesis Inhibitors
Share to Benzenesulfonates

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug-Related Side Effects and Adverse Reactions

Share to Magnetic Resonance Angiography

Share to Neovascularization, Pathologic

Share to Niacinamide

Share to Phenylurea Compounds

Share to Sorafenib

Source

Open in PubMed Open full text

Identifiers

PMID: 21224376
DOI: 10.1158/1078-0432.CCR-10-2331
PMCID: PMC3048919

Genes

KRAS
EGFR
BID

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Evaluation of KRAS mutations, angiogenic biomarkers, and DCE-MRI in patients with advanced non-small-cell lung cancer receiving sorafenib.PMID 21224376Read ↗

A multicenter phase II study of sorafenib in combination with erlotinib in patients with advanced non-small cell lung cancer (KCSG-0806).Semantic proximity Read ↗

A phase II study of sorafenib in patients with platinum-pretreated, advanced (Stage IIIb or IV) non-small cell lung cancer with a KRAS mutation.Semantic proximity Read ↗

A phase II trial of sorafenib in metastatic melanoma with tissue correlates.Semantic proximity Read ↗

Monotherapy Administration of Sorafenib in Patients With Non-Small Cell Lung Cancer (MISSION) Trial: A Phase III, Multicenter, Placebo-Controlled Trial of Sorafenib in Patients with Relapsed or Refractory Predominantly Nonsquamous Non-Small-Cell Lung Cancer after 2 or 3 Previous Treatment Regimens.Semantic proximity Read ↗

First-line erlotinib and bevacizumab in patients with locally advanced and/or metastatic non-small-cell lung cancer: a phase II study including molecular imaging.Semantic proximity Read ↗

Phase I study of the combination of sorafenib and temsirolimus in patients with metastatic melanoma.Semantic proximity Read ↗

Phase II study of bevacizumab in combination with sorafenib in recurrent glioblastoma (N0776): a north central cancer treatment group trial.Semantic proximity Read ↗

Biomarker Analysis in a Phase II Study of Sunitinib in Patients with Advanced Melanoma.Semantic proximity Read ↗

Sorafenib efficacy in thymic carcinomas seems not to require c-KIT or PDGFR-alpha mutations.Semantic proximity Read ↗

Dual antiangiogenic inhibition: a phase I dose escalation and expansion trial targeting VEGF-A and VEGFR in patients with advanced solid tumors.Semantic proximity Read ↗

A first-in-human phase I, multicenter, open-label, dose-escalation study of the oral RAF/VEGFR-2 inhibitor (RAF265) in locally advanced or metastatic melanoma independent from BRAF mutation status.Semantic proximity Read ↗

Correlation between early 18F-FDG PET/CT response to BRAF and MEK inhibition and survival in patients with BRAF-mutant metastatic melanoma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.